MARKET

MESO

MESO

Mesoblast
NASDAQ
11.35
+0.38
+3.46%
Closed 18:37 05/12 EDT
OPEN
11.23
PREV CLOSE
10.97
HIGH
11.47
LOW
11.12
VOLUME
98.44K
TURNOVER
0
52 WEEK HIGH
22.00
52 WEEK LOW
5.78
MARKET CAP
1.44B
P/E (TTM)
-12.4247
1D
5D
1M
3M
1Y
5Y
1D
Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating
Seeking Alpha · 14h ago
Weekly Report: what happened at MESO last week (0505-0509)?
Weekly Report · 1d ago
Weekly Report: what happened at MESO last week (0428-0502)?
Weekly Report · 05/05 09:03
Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials
Seeking Alpha · 05/05 06:44
Mesoblast reports Q3 results
Seeking Alpha · 05/01 12:45
Mesoblast Limited (MEOBF) Receives a Buy from Bell Potter
TipRanks · 05/01 00:36
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
Barchart · 04/29 19:53
MESOBLAST APPOINTS CORPORATE FINANCE LEADER LYN COBLEY TO BOARD
Reuters · 04/28 23:44
More
About MESO
More
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
Recently
Symbol
Price
%Change

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.